A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants

CompletedOBSERVATIONAL
Enrollment

658

Participants

Timeline

Start Date

May 28, 2019

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
Liver NeoplasmsCarcinoma, Hepatocellular
Interventions
OTHER

Non-interventional

No intervention will be administered.

Trial Locations (42)

Unknown

Site #32, Cheonan

Site #35, Bucheon-si

Site #38, Bucheon-si

Site #06, Goyang-si

Site #03, Seongnam-si

Site #13, Suwon

Site #27, Suwon

Site #15, Uijeongbu-si

Site #37, Changwon

Site #28, Yangsan

Site #29, Yangsan

Site #31, Busan

Site #39, Busan

Site #40, Busan

Site #17, Daegu

Site #18, Daegu

Site #26, Daegu

Site #30, Daegu

Site #41, Daegu

Site #19, Daejeon

Site #20, Daejeon

Site #24, Daejeon

Site #34, Daejeon

Site #21, Incheon

Site #33, Incheon

Site #36, Incheon

Site #01, Seoul

Site #02, Seoul

Site #04, Seoul

Site #07, Seoul

Site #08, Seoul

Site #09, Seoul

Site #10, Seoul

Site #12, Seoul

Site #16, Seoul

Site #22, Seoul

Site #23, Seoul

Site #25, Seoul

Site #42, Seoul

Site #43, Seoul

Site #44, Seoul

Site #11, Ulsan

All Listed Sponsors
lead

Eisai Korea Inc.

INDUSTRY

NCT05225207 - A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants | Biotech Hunter | Biotech Hunter